OBJECTIVES: @entity340 ( @entity340 ) is an inflammatory process and not a result of normal ageing. The @entity3808 process is accelerated by risk factors such as smoking and high @entity165 levels. The genetic factors for the development of @entity340 are however unknown. Therefore the purpose of the present study was to investigate whether polymorphisms in the @entity2931 receptor alpha (ORalpha) gene and in the @entity2533 ( @entity2533 ) gene were related to the presence of @entity340 in postmenopausal @entity1 . DESIGN: Case-control study. SUBJECTS AND METHODS: Relationships were tested between polymorphisms in the ORalpha gene defined by the restriction enzymes PvuII and XbaI, and in the @entity2533 gene defined by AocI, and @entity340 , @entity3452 [ @entity3452 ] in 41 postmenopausal female @entity1 and 41 age- and sex-matched controls. These polymorphisms were also tested in relation to lipid levels and @entity3452 , in 99 healthy Caucasian @entity1 , aged 16.9 +/- 1.2 years. RESULTS: In the postmenopausal @entity1 and age-matched controls, the PvuII polymorphism was independently associated with an increased risk of @entity340 [odds ratio (OR) = 3.38; 95% confidence interval (CI) 1.13-10.09). A genotype defined by at least one restriction site in the PvuII polymorphism and two restriction sites in the @entity2533 polymorphism was related to a highly significantly increased risk of @entity340 (OR = 4.58; 95% CI 1.68-12.51). In the adolescent female cohort, presence of two restriction sites in the PvuII polymorphism was associated with higher levels of total @entity165 (TC) (P = 0.02), and low-density lipoprotein @entity165 (LDL) (P = 0.04). CONCLUSIONS: We have demonstrated that the PvuII polymorphism in the ORalpha gene is related to both the presence of @entity340 in postmenopausal @entity1 and to lipid levels in adolescent females, suggesting that this polymorphism may influence the risk of @entity340 partly by affecting lipid levels.

@entity2931 receptor alpha gene polymorphism is related to aortic valve sclerosis in postmenopausal XXXX .

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'girls'] @entity2931 :: ('CHEBI:50114', 'Chemical') :: ['oestrogen'] @entity3808 :: ('MESH:C538213', 'Disease') :: ['sclerotic'] @entity3452 :: ('4018', 'Gene') :: ['Lp(a)', 'lipid levels, and lipoprotein(a)'] @entity2533 :: ('7040', 'Gene') :: ['TGF-beta1', 'transforming growth factor beta'] @entity340 :: ('MESH:D006349', 'Disease') :: ['AS', 'Aortic valvular sclerosis'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity1 :: (9606,Species) :: ['women']
